Major Growth Driver Identified in 2025 Non-Proliferative Diabetic Retinopathy Market: Surging Prevalence Of Diabetes Fuels Growth In The Non-Proliferative Diabetic Retinopathy Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Non-Proliferative Diabetic Retinopathy Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for non-proliferative diabetic retinopathy has seen significant growth recently, expanding from $2.62 billion in 2024 to $2.84 billion in 2025, with an 8.4% compound annual growth rate (CAGR). The increased growth during this historical period is attributable to several factors, including the rising number of diabetes cases, an older population, heightened awareness, advancements in research, modifications in lifestyle, and enhancements in diabetes control.

Non-Proliferative Diabetic Retinopathy Market Size Forecast: What's the Projected Valuation by 2029?
In the coming years, the market size for non-proliferative diabetic retinopathy is projected to experience robust growth, reaching $3.87 billion in 2029 with a compound annual growth rate (CAGR) of 8.0%. The anticipated growth during the forecast period is due to factors such as the adoption of telemedicine, novel therapeutic developments, the incorporation of artificial intelligence, heightened investment in research and development, and improvements in healthcare infrastructure. Key trends for the forecast period encompass an increased utilization of artificial intelligence for screening and diagnosis, a surge in demand for telemedicine and remote patient monitoring, the emergence of personalized medicinal approaches for diabetic retinopathy, an intensified focus on prevention and early intervention, and the broadening scope of patient-centric care models in diabetic retinopathy management.

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report

What Are the Drivers Transforming the Non-Proliferative Diabetic Retinopathy Market?
The non-proliferative diabetic retinopathy market's growth is predicted to be enhanced by the escalating frequency of diabetes. The enduring metabolic condition, diabetes, is outlined by excessive glucose in the blood due to insufficient insulin secretion by the pancreas or insulin resistance of the body's cells. Unhealthy eating habits, inactive lifestyles, and genetic factors are the culprits for the onset of diabetes. Diabetes triggers non-proliferative diabetic retinopathy by damaging retina's blood vessels primarily due to the extensive exposure to raised glucose levels in the blood, resulting in vision loss and even possible blindness. As per the data provided by the National Health Service, a UK government department, in June 2024, back in 2023, NHS discovered an extra 549,000 individuals at risk of developing type 2 diabetes in England. This increased the total count of people diagnosed with non-diabetic hyperglycemia, or pre-diabetes registered with a GP, to 3,615,330, representing a major increase compared to 3,065,825 in 2022, a surge of almost 20%. Hence, the rise in diabetes occurrence is catalyzing the growth of the non-proliferative diabetic retinopathy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15620&type=smp

What Long-Term Trends Will Define the Future of the Non-Proliferative Diabetic Retinopathy Market?
Prominent businesses in the non-proliferative diabetic retinopathy sector are creating AI-powered cameras to heighten patient results and push forward in the sector of ocular imaging. AI-supported cameras in this arena are devices that incorporate artificial intelligence (AI) algorithms that aid in capturing, scrutinizing, and understanding eye images for diagnosis and treatment applications. For example, in May 2024, Optomed, a medtech firm from Finland, introduced the Optomed Aurora AEYE, a handheld AI fundus camera engineered to promptly identify more than mild diabetic retinopathy. This ground-breaking gadget merges the convenience of a handheld camera with sophisticated AI, delivering superior quality retinal visuals for the preliminary identification and tracking of multiple eye disorders. The Optomed Aurora AEYE employs AI algorithms to support medical practitioners in examining retinal images, facilitating fast and accurate diagnoses of conditions like diabetic retinopathy, glaucoma, and age-related macular degeneration.

Which Segments in the Non-Proliferative Diabetic Retinopathy Market Offer the Most Profit Potential?
The non-proliferative diabetic retinopathy market covered in this report is segmented -

1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy
2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users

Subsegments:
1) By Anti-Vascular Endothelial Growth Factor (Vegf) Therapy: Bevacizumab (Avastin), Ranibizumab (Lucentis), Aflibercept (Eylea), Pegaptanib (Macugen)
2) By Intraocular Steroid Injection: Triamcinolone Acetonide, Dexamethasone Implant (Ozurdex), Fluocinolone Acetonide Implant (Iluvien)
3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy (Ppv), Membrane Peeling Vitrectomy, Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15620&type=smp

Which Firms Dominate the Non-Proliferative Diabetic Retinopathy Market by Market Share and Revenue in 2025?
Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Ampio Pharmaceuticals, Kowa Company Ltd., Nidek Co. Ltd.

Which Regions Offer the Highest Growth Potential in the Non-Proliferative Diabetic Retinopathy Market?
North America was the largest region in the non-proliferative diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15620

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.